NH Nongwoo Bio 2026 Q1 Consolidated Sales KRW 36.4B, Operating Profit KRW 5.4B… Dividend of KRW 4B Maintained

[Revenue & Profitability] Consolidated Q1 sales KRW 36.4B (down 2.7% YoY), operating profit KRW 5.4B (down 28.9% YoY), net profit attributable to parent KRW 6.4B (down 1.5% YoY), EPS KRW 400
[Business Segments] Seed sales KRW 29.7B (81.6%), Agri-material sales KRW 6.7B (18.4%). Overseas seed sales account for 50.7%
[Financial Soundness] Debt ratio 27.1%, cash equivalents KRW 32.2B. Credit rating A- (NICE, cash flow grade CF1 excellent)
[Shareholder Return] Decided year-end dividend of KRW 250 per share (total KRW 4.0B) for 37th fiscal year, payout ratio 32.6%. Consecutive dividend maintained
[R&D] Q1 R&D investment KRW 4.0B (11.1% of sales), holding 120 plant variety protection rights
[Risk]Derivative (TRF) valuation loss of KRW 0.55B incurred, 4 pending lawsuits (total approx. KRW 1.3B)